Helix BioPharma Corp. (HBP)

Toronto
0.210
0.000(0.00%)
  • Volume:
    0
  • Bid/Ask:
    0.190/0.230
  • Day's Range:
    0.210 - 0.210
Earnings results expected in 5 days

Helix BioPharma Corp. will announce its quarterly financial results in 5 days. Traders should take this into account as the share price often fluctuates around this time period.

HBP Overview

Prev. Close
0.21
Day's Range
0.21-0.21
Revenue
-
Open
0.21
52 wk Range
0.16-0.45
EPS
-0.044
Volume
0
Market Cap
41.48M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
7,932
P/E Ratio
-5.24
Beta
-0.552
1-Year Change
-54.35%
Shares Outstanding
197,511,530
Next Earnings Date
Dec 14, 2022
What is your sentiment on Helix BioPharma Corp.?
or
Market is currently closed. Voting is open during market hours.

Helix BioPharma Corp. News

Helix BioPharma Corp. Analysis

Helix BioPharma Corp. Company Profile

Helix BioPharma Corp. Company Profile

Employees
7
Market
Canada
  • Type:Equity
  • Market:Canada
  • ISIN:CA4229101098
  • CUSIP:422910109

Helix BioPharma Corp. operates as an immune-oncology company in Canada. The company is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. It has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. The company is headquartered in Toronto, Canada.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellStrong Sell
Technical IndicatorsSellSellSellStrong SellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell
  • it got approved by FDA From USA for new drugs
    0
    • Looks like some insiders know something we don't
      0